📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Vimta Labs Q3 FY26 Revenue Up 10.2% YoY to ₹100.5 Cr; 9M Profit Grows 16.4%
Vimta Labs reported a 10.2% YoY revenue growth in Q3 FY26, reaching ₹100.5 crores, although it experienced a 3.9% sequential decline due to operational restructuring and clinical order lags. The 9-month performance remains strong with total income rising 20.7% to ₹304.3 crores and PAT increasing 16.4% to ₹56.4 crores. The company is expanding into biologics CRDMO services, expected to commercialize in Q1 FY27, and maintains a net debt-free balance sheet. Management expects a stronger Q4 performance, aligning with historical seasonal trends.
Key Highlights
Q3 FY26 revenue grew 10.2% YoY to ₹100.5 crores, while 9M FY26 revenue rose 20.7% to ₹304.3 crores.
EBITDA for 9M FY26 stood at ₹106.8 crores with a healthy margin of 35.1%.
Recognized a one-time exceptional cost of ₹1.6 crores due to new labor law implementation.
Biologics contract research and development services are scheduled for commercialization by Q1 FY27.
EMI/EMC testing facility is operating at 80-85% utilization, with a second chamber installation on track.
💼 Action for Investors
Investors should monitor the successful commercialization of the biologics segment in FY27 and the recovery of clinical research order bookings. The company's debt-free status and strong margins in the TIC sector provide a stable long-term outlook.
Vimta Labs Q3 FY26 Total Income Rises 10.2% YoY to ₹1,005 Mn; PAT Flat at ₹176 Mn
Vimta Labs reported a 10.2% YoY increase in total income for Q3 FY26, reaching ₹1,005 million, though revenue declined 3.9% on a sequential basis. Net profit remained nearly flat YoY at ₹176 million, with margins facing pressure as the EBITDA margin contracted to 34.3% from 37.6% in the previous year. The margin compression was partly attributed to exceptional items related to the impact of New Labour Codes. However, the nine-month (9M FY26) performance remains robust, with total income growing 20.7% and PAT increasing 16.4% YoY.
Key Highlights
Total Income for Q3 FY26 stood at ₹1,005 Mn, up 10.2% YoY but down 3.9% QoQ.
EBITDA margin contracted to 34.3% in Q3 FY26 compared to 37.6% in Q3 FY25.
9M FY26 Total Income grew significantly by 20.7% YoY to ₹3,043 Mn.
Net Profit for 9M FY26 increased by 16.4% YoY to ₹564 Mn with an EPS of ₹12.67.
Margins were impacted by exceptional costs related to the implementation of New Labour Codes.
💼 Action for Investors
Investors should monitor the impact of the New Labour Codes on future margins to see if the current compression is transitory. While the 9-month growth trajectory is strong, the sequential dip in revenue and profit warrants a cautious watch on near-term demand.
Vimta Labs Q3 FY26 Total Income up 10.2% YoY to ₹1,005 Mn; 9M PAT Grows 16.4%
Vimta Labs reported a steady performance for Q3 FY26 with total income reaching ₹1,005 Mn, a 10.2% YoY increase. For the 9-month period (9M FY26), the company showed robust growth with revenue rising 20.7% to ₹3,043 Mn and PAT increasing 16.4% to ₹564 Mn. EBITDA margins remain healthy at 35.1% for the 9M period, supported by a strong balance sheet featuring minimal debt of ₹45.2 Mn and significant cash reserves of ₹666.6 Mn. The company continues to invest in growth, reporting a Q3 capex outflow of ₹248.3 Mn.
Key Highlights
9M FY26 Total Income grew by 20.7% YoY to ₹3,043 Mn compared to ₹2,521 Mn in 9M FY25
9M FY26 PAT increased by 16.4% YoY to ₹564 Mn with a healthy PAT margin of 18.5%
EBITDA for Q3 FY26 stood at ₹344 Mn with a margin of 34.3%, despite a ₹16 Mn exceptional item for labor codes
Maintains a very low Debt-to-Equity ratio of 0.01 with total debt of only ₹45.2 Mn
Significant infrastructure footprint with over 600,000 sq. ft. of lab space and 1,300+ employees
💼 Action for Investors
Investors should view the consistent double-digit revenue growth and strong margin profile as a sign of operational efficiency in the TIC industry. The company's extremely low leverage and high cash reserves provide a strong cushion for future expansion.
Vimta Labs Q3 FY26: Revenue Grows 9.7% YoY to ₹986M; PAT Steady at ₹176M
Vimta Labs reported a 9.7% YoY growth in revenue from operations for Q3 FY26, reaching ₹986.33 million. Net profit from continuing operations remained nearly flat at ₹175.86 million compared to ₹175.16 million in the previous year, largely due to a one-time exceptional charge of ₹16.16 million related to the implementation of new labour codes. For the nine-month period, the company showed stronger performance with revenue increasing 19.4% and net profit rising 16.4% YoY. The company continues to focus on its core contract research and testing services following the divestment of its diagnostics business.
Key Highlights
Revenue from operations increased to ₹986.33 million in Q3 FY26 from ₹899.23 million in Q3 FY25.
Net profit for the quarter stood at ₹175.86 million, including a ₹16.16 million exceptional cost for gratuity adjustments under new labour codes.
9M FY26 total income reached ₹3,042.83 million, a significant jump from ₹2,521.41 million in the same period last year.
Basic EPS for the quarter was ₹3.96, compared to ₹3.93 in the year-ago period (adjusted for the 1:1 bonus issue).
The Board approved the grant of 38,269 new ESOP options to eligible employees.
💼 Action for Investors
The steady revenue growth in the core testing business is positive, though margins were temporarily impacted by statutory exceptional items. Long-term investors should monitor the scalability of the National Food Testing Laboratory (PPP project) and the impact of labour code revisions on operating margins.
Vimta Labs Q3 Net Profit at ₹175.86 Mn; 9M Revenue Grows 19% YoY
Vimta Labs reported a steady Q3 FY26 with revenue from operations reaching ₹986.33 million, a 9.7% growth compared to the same quarter last year. Net profit for the quarter stood at ₹175.86 million, which remained relatively flat YoY due to a one-time exceptional charge of ₹16.16 million related to new labor code compliance. For the nine-month period ending December 2025, the company showed robust performance with total income rising to ₹3,042.83 million from ₹2,521.41 million in the previous year. The company has successfully transitioned its focus to core contract research and testing services following the divestment of its diagnostic business.
Key Highlights
Revenue from operations for Q3 FY26 grew 9.7% YoY to ₹986.33 million.
Net Profit for the nine-month period (9M FY26) increased by 16.4% to ₹563.99 million.
Recorded a one-time exceptional expense of ₹16.16 million for gratuity adjustments under new labor codes.
Basic EPS for the quarter stood at ₹3.96, adjusted for the 1:1 bonus issue completed in June 2025.
The Board approved the grant of 38,269 new ESOP options to eligible employees.
💼 Action for Investors
Investors should monitor the company's ability to maintain margins in its core testing segment now that the lower-margin diagnostic business has been divested. The steady YoY growth in the nine-month period suggests a positive trajectory for the core business.
Vimta Labs Q3 Revenue Grows 9.7% YoY to ₹986M; PAT at ₹175.8M Impacted by Exceptional Item
Vimta Labs reported a steady 9.7% year-on-year growth in revenue from continuing operations, reaching ₹986.33 million for Q3 FY26. Net Profit for the quarter stood at ₹175.86 million, a decline from ₹214.96 million in the previous year's quarter, largely due to a ₹16.16 million exceptional charge related to new labor codes and the absence of discontinued diagnostic business income. Employee benefit expenses saw a significant rise to ₹284.05 million compared to ₹233.66 million YoY. The company has now fully transitioned away from its diagnostic business, focusing entirely on contract research and testing services.
Key Highlights
Revenue from operations increased 9.7% YoY to ₹986.33 million in Q3 FY26.
Net Profit for the quarter stood at ₹175.86 million, down from ₹214.96 million in Q3 FY25.
Recorded an exceptional item of ₹16.16 million due to the statutory impact of new Labour Codes.
Employee benefit expenses rose by 21.5% YoY to ₹284.05 million.
Nine-month revenue for FY26 reached ₹2,980.45 million, up from ₹2,495.41 million in the previous year.
💼 Action for Investors
Investors should monitor the company's margin profile as it navigates rising employee costs and the impact of new labor regulations. While core revenue growth remains healthy, the stock's performance will depend on the successful scaling of its contract research services post-divestment of the diagnostics arm.
Vimta Labs Q3 PAT at ₹175.9M; Revenue Grows 9.7% YoY to ₹986.3M
Vimta Labs reported a steady 9.7% year-on-year growth in revenue from operations, reaching ₹986.33 million for Q3 FY26. Net profit for the quarter stood at ₹175.86 million, remaining nearly flat compared to ₹175.16 million from continuing operations in the same quarter last year. The bottom line was impacted by a one-time exceptional charge of ₹16.16 million due to the implementation of new labor codes. The company is now fully focused on its core Contract Research and Testing Services following the divestment of its diagnostics business to Thyrocare.
Key Highlights
Revenue from operations increased 9.7% YoY to ₹986.33 million from ₹899.23 million.
Net Profit for the quarter stood at ₹175.86 million, facing a sequential decline from ₹199.20 million in Q2.
Recognized an exceptional item of ₹16.16 million related to past service costs for gratuity under new Labour Codes.
Nine-month (9M FY26) revenue reached ₹2,980.45 million, up 19.4% compared to ₹2,495.41 million in 9M FY25.
The Board approved the grant of 38,269 new ESOP options to eligible employees.
💼 Action for Investors
Investors should monitor the company's margin stability as it scales its core research business post-diagnostics divestment. While YoY growth is healthy, the sequential dip in performance suggests a need for cautious observation of upcoming quarters.